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Background: Angiogenesis inhibitors have become an important therapeutic approach
in the treatment of hepatocellular carcinoma (HCC) patients. The therapeutic inhibition
of angiogenesis of Sorafenib in increasing overall survival of patients with HCC is a
fundamental element of the treatment of this disease. Considering the heterogeneous
aspects of HCC and to boost therapeutic efficacy, prevail over drug resistance and lessen
toxicity, adding antiangiogenic drugs to antiblastic chemotherapy (AC), radiation therapy
or other targeted drugs have been evaluated. The matter is additionally complicated
by the combination of antiangiogenesis with further AC or biologic drugs. To date, no
planned approach to understand which patients are more responsive to a given type of
antiangiogenic treatment is available.
Conclusion: Large investments in the clinical research are essential to improve
treatment response and minimize toxicities for patients with HCC. Future investigations
will need to focus on utilizing patterns of genetic information to classify HCC into groups
that display similar prognosis and treatment sensitivity, and combining targeted therapies
with AC producing enhanced anti-tumor effect. In this review the current panel of available
antiangiogenic therapies for the treatment of HCC have been analyzed. In addition current
clinical trials are also reported herein.
Keywords: neo-angiogenesis, hepatocellular carcinoma, treatment, target therapy, inhibitors and toxicity,
pharmacogenomics
INTRODUCTION
The growth of cancers and the development of metastasis depend on angiogenesis, that is the
adequate structure for blood supply, (Bruix et al., 2014a; Kubo et al., 2016). The process of
angiogenesis consists of multiple, and mutually dependent steps. It begins with local degeneration
of the basement membrane near capillaries, then by the invasion of the nearby stroma by the
primary endothelial cells in the direction of the angiogenic stimuli. Endothelial cells migration
is followed by the increase of endothelial cells, organized into 3D structures joining with new
analogous structures forming a system of new blood vessels.
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This is sometimes referred to as sprouting angiogenesis, which
is a local process. In addition, endothelial cells can be generated
not only by the division of pre-existing differentiated endothelial
cells but also by the influx of circulating endothelial progenitor
cells from bone marrow, a process sometimes referred to as
systemic vasculogenesis (Kubo et al., 2016).
The beginning of angiogenesis affects the equlibrium between
pro-angiogenic and antiangiogenic molecules in the local tissue
microenvironment (Bruix et al., 2014a; Garbuzenko et al., 2016;
Kubo et al., 2016). These molecules mediate multiple steps in the
process of angiogenesis by selectively altering the characteristics
of endothelial cells and associated perivascular structures (i.e.,
pericytes, vascular smooth muscle cells). Angiogenesis can occur
by either emergent or non-emergent processes (Garbuzenko
et al., 2016). Emergent angiogenesis implicates the division
of new small vessels from pre-existing vessels. Non-emergent
angiogenesis results from the enlargement, splitting, and
fusion of pre-existing vessels produced by the proliferation of
endothelial cells within the wall of a vessel. Trans-vascular
bridges are occasionally observed in enlarged vessels produced
by non-sprouting angiogenesis (Garbuzenko et al., 2016). This
type of angiogenesis can occur concurrently with sprouting
angiogenesis in the vascularization of organs or tissues. The
mechanism of non-sprouting angiogenesis was found in brain
metastases, and vascular endothelial growth factor (VEGF), also
called vascular permeability factor (VPF) (Mazzaferro et al., 2014;
Kim et al., 2015; Zampino et al., 2015), has a pivotal role in
developmental, physiologic and pathologic neo-vascularization.
Vascular endothelial growth factor is a homodimeric heparin-
binding glycoprotein that exists in at least four isoforms. The
isoforms are subdivided in VEGF121, VEGF165, VEGF189, and
VEGF205 according to the number of amino acids that each
protein has.
There are at least four other members of the VEGF family.
The aforementioned VEGF is referred to as VEGF-A. VEGF-B
is believed to play a fundamental role in vasculogenesis; it may
have also other roles like the activation of enzymes with invasive
action on endothelial cells (Cervello et al., 2012; Mazzaferro
et al., 2014). VEGF-C is frequently associated with lymph-
angiogenesis, but more recently, its expression has been related
with tumor angiogenesis in several systems. The role of VEGF-D
is not so defined, but it may attach to VEGF receptor-2 (VEGFR-
2) and VEGFR-3, and may induce in vivo angiogenesis. Little is
known about VEGF-E, except that it binds to VEGFR-2 and can
induce endothelial cell mitosis and angiogenesis (Cervello et al.,
2012). VEGF receptors are expressed on endothelial cells and
some tumor cells (Mazzaferro et al., 2014).
Among these molecules, VEGF is the most relevant factor
for maintaining tumor cells growth and mediates its activity
by specific receptors, called VEGF receptors (VEGFRs). VEGF
is the target of numerous anti-cancer medications helpful in
the management of many cancers including colon cancer,
ovarian cancer, and glioblastoma multiforme (Korpanty and
Smyth, 2012; Falchook et al., 2013; Ellingson et al., 2014).
The primary angiogenic receptors for VEGF is VEGFR-1 and
VEGFR-2. VEGFR-1 and VEGFR-2 are expressed in some types
of vascular endothelial and cancer cells. VEGFRs are part of
the tyrosine kinase receptors (TKr) family. VEGFR consists in
seven extracellular immunoglobulin-like domains containing the
tyrosine kinase domain (TKD). The binding between VEGF and
its receptor origins the VEGFRs’ dimerization, leading to the
activation of intrinsic TK (Koch et al., 2011). Different VEGFRs
create different signals, regardless of the elevated homology
within the TKD. VEGFR-1 as a regulatory role in angiogenesis
is scarcely autophosphorylated by VEGF in endothelial cells.
In addition to TKr pathways, when considering growth
factors such as VEGF, discussing signaling events that are
activated by cell-cell or cell-matrix interactions are highly
important. Noteworthy is the crucial role of the downstream
RAS/RAF/mitogen-activated protein extracellular kinase
(MEK)/extracellular signal-regulated kinase (ERK) signaling
pathway, and activated Rac1 (Wang and Hartnett, 2016).
The new angiogenesis inhibitor agents target these alternative
signaling pathway (Figure 1).
Nevertheless, current clinical trials have demonstrated that
VEGFR-1, as a fundamental mediator of both physiologic
and developmental angiogenesis may direct to the aggressive
actions of HCC cells (Yi et al., 2011). VEGFR-2, mediating the
development of endothelial cells and their permeability to cells
and molecules upon binding of VEGF is directly implicated in
angiogenesis process (Shibuya and Claesson-Welsh, 2006). A
preclinical study in murine has exposed that the combination
of anti-VEGFR-1 and anti-VEGFR-2 molecules might efficiently
inhibit the expansion of HCC (Yoshiji et al., 2004). Current
clinical trials are reported in this review.
Thus far, agents that target VEGF ligand-receptor system have
been reported to have mild toxicity in clinical trials compared
to that of standard chemotherapy; on the other hand, adverse
effects have been reported (i.e., hypertension, nausea, headaches,
thrombotic events, and proteinuria). The long-term effects of
antiangiogenic therapy are yet unidentified.
Background of Hepatocellular Carcinoma
HCC is the most frequent primary cancer of the liver and
is the 5th and the 3rd leading cause of death from cancer
worldwide in women and men, respectively (Ursino et al., 2012).
Historically, the best known risk factors are represented by
HBV, HCV virus infection (Berretta et al., 2015) and alcohol
abuse with the resulting complications. Despite the potential
decline of HCV cirrhosis in the coming years to the advent of
new antiviral therapies, the increase of metabolic and NASH,
constitute additional elements of risk (Thomas, 1996; Risau,
1997). A range of therapies are used in the management of HCC;
the best outcomes are seen in patients who fulfill the criteria to
undergo liver transplantation, surgical resection or loco regional
therapies including transarterial chemoembolization (TACE),
radiofrequency ablation and percutaneous ethanol injection
(Senger et al., 1983; Ferrara et al., 2003; D’Amico et al., 2015a).
More recently, the identification of cellular pathways playing a
key role in the pathogenesis of HCC, primarily neoangiogenesis,
has led to development of targeted drugs (Veikkola et al., 2000;
Canzonieri et al., 2015) (Figure 1). Recent studies have described
several mutational profile in HCC (Cervello et al., 2012; Falchook
et al., 2013; Mazzaferro et al., 2014). Deep-sequencing studies
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FIGURE 1 | Schematic signaling pathways elicited by VEGF. The Tyrosine kinase proteins, Serine/Threonine Kinase (AKT etc), and GTPase (K-Ras) pathways are
illustrated inside the cytoplasm compartment. The drugs (blu boxes) are indicative for their target that blocks/inhibit their effect on neo-angiogenesis, cell proliferation,
apoptosis and etc. VEGFR family is composed by VEGFR1 (Alias FLT1), VEGFR2 (Alias KDR), VEGFR3 (Alias NRP1). Receptors for growth factors (VEGFR, FGFR,
PDGFR) activate intracellular receptor tyrosine kinases (RTKs) and the downstream RAS/RAF/mitogen-activated protein extracellular kinase (MEK)/extracellular
signal-regulated kinase (ERK) signaling pathway, and promote the growth, migration and morphogenesis of vascular endothelial cells, thus increasing vascular
permeability by activating nuclear proteins (yellow boxes). Angiopoietin 1, 2 (Tie1,2) and VEGF are the principal angiogenic growth factors.
have confirmed that promoter region of TP53 and β-Catenin
1 (CTNNB1) are frequently mutated in about 33 and 22% of
HCC patients, respectively (Hirotsu et al., 2016). Mutations in
these genes are mutually exclusive, an indication that they could
act as drivers of tumor progression (Zhu et al., 2006; Sun et al.,
2011). Overall, signaling pathways and apoptosys are altered
in the multistep process of liver carcinogenesis. Sorafenib is a
multi-targeted TK inhibitor, which is the only systemic agent
found to increase survival time in patients with locally advanced
and/or metastatic HCC (Berretta et al., 2013). In particular, it has
been shown to improve survival by 2.3–2.8 month and currently
represents the standard of care for these patients (Santoro et al.,
2013). Novel targeted drugs are in the development stage but
clinical trials have not provided satisfactory results to date.
VEGF is over expressed in HCC and is correlated with poorer
clinical outcomes. This suggests that VEGF-mediated signaling is
fundamental in HCC pathogenesis and it is a therapeutic target
(Zhu et al., 2011).
Can We Improve Angiogenesis Therapy in
HCC?
Considering the clinical and biological characteristics of HCC,
patient enrichment therapeutic strategies or selection would be
crucial to show a benefit in overall survival (OS) (Llovet and
Hernandez-Gea, 2014).
The clinical outcomes of therapy in HCC could be
improved by combining antiangiogenic agents and antiblastic
chemotherapy (AC) and or other targeted molecules.
Combined treatments with bevacizumab plus CAPOX
(capecitabine and oxaliplatin) or with bevacizumab plus
GEMOX (gemcitabine and oxaliplatin) in HCC patients
accounted in median survivals of less than 10 months (Zhu et al.,
2006; Sun et al., 2011). On the basis of hopeful results from plus
doxorubicin sorafenib in HCC, a phase III randomized trial
(CALGB80802) comparing sorafenib alone vs. sorafenib plus
doxorubicin is ongoing in patients with advanced HCC (Berretta
et al., 2013). Other study combining sorafenib with GEMOX,
modified FOLFOX (Folate, 5-FU and oxaliplatin), or CAPOX
are ongoing.
Another approach has evaluated the join of antiangiogenic
therapy with tyrosin Kinase inhibitors (TKI) of other targeted
drugs. In a randomized phase II trial in advanced HCC,
Tivantinib, a c-MET inhibitor, in comparison with placebo,
demonstrated an augmented time to progression (TTP),
particularly in tissue of patients bearing high MET expression
(Santoro et al., 2013). Another example is Cabozantinib, a TKI
of c-MET/VEGF receptor 2 (VEGFR2), is undergoing a phase
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TABLE 1 | Main characteristics of angiogenesis inhibitor drugs.
Drugs Typology Targets HCC therapeutic indication and ongoing study
Bevacizumab Monoclonal antibody VEGF Phase II study in combination with Erlotinib
(NCT00881751)
Brivanib Small molecule multikinase inhibitor VEGFR, FGF Advanced stage, Phase III study in patients who failed
Sorafenib (NCT00825955), and first line (NCT00858871)
Cabozatinib Small molecule multikinase inhibitor c-MET, RET, VEGFR1-3, c-KIT, Preclinical study, yet
Cediranib Small molecule multikinase inhibitor VEGFR 2, PDGFR, c-Kit Advanced stage, phase II study
Everolimus Small molecule m-TOR Not registered; phase III study did not show significant
efficacy
Lenvatinib Small molecule multikinase inhibitor VEGFRs 1, 2 and 3, FGFRs 1 PDGFRα, RET,
KIT
Not registered; phase III trial underway (NCT01761266)
Linifanib Small molecule multikinase inhibitor VEGFR 2, PDGFR families Advanced stage, phase III study first-line vs. sorafenib
(NCT01009593)
Nintedanib Small molecule multikinase inhibitor VEGFRs 1, 2 and 3, FGFRs 1 PDGFR phase design study vs. sorafenib (NCT00987935 and
NCT01004003)
Ramucirumab Monoclonal antibody Selective VEGFR 2 Not registered; phase III study with conflicting results
Refametinib Small molecule mitogen-activated
protein kinase inhibitor
MEK 1-2 Advanced stage, phase II study in patients who failed
sorafenib (NCT01915589) and in combination with
sorafenib (NCT01915602)
Regorafenib Small molecule multikinase inhibitor VEGFR1-3, c-KIT, TKI-like, EGF-like 2, PDGF 2,
FGF 1, RET, RAF-1, BRAF, MAPK
Not registered; phase III study underway recruiting patients
who progressed under sorafenib (NCT01774344)
Sorafenib Small molecule multikinase inhibitor VEGFR 2, PDGFR, c-Kit, BRAF Advanced stage; not recommended for use in adjuvant
treatment
Trebananib Small molecule angiogenesis
inhibitor
Tie-2 (Angiopoietin) Not registered; phase II study no showed improvement of
OS
Vatalanib Small molecule angiogenesis
inhibitor
VEGFRs 1, 2 and 3, PDGFR c-FMS Advanced stage, phase II in combination with Doxorubicin
III valuation in HCC patients who not tolerate or did failed
treatment with sorafenib (Verslype et al., 2012). Everolimus, a m-
TOR inhibitor, in a randomized phase III trial (EVOLVE-1) has
been compared with best supportive care alone in the second-line
treatment of HCC patients relapsed from sorefinib. Evenmore, no
significant survival advantage has been demonstrated (Zhu et al.,
2014a). Everolimus has been also used together sorafenib in a
phase I trial; preliminary results shown a development of grade
3/4 thrombocytopenia in 43% of the HCC patients (Finn et al.,
2013).
MATERIALS AND METHODS
With the aim to evaluate the actual sceneries of angiogenesis
inhibitors for the treatment of HCC, a search on the Cochrane
Library and PubMed has been performedmatching the key words
“angiogenesis inhibitors treatment,” “target therapy,” and “HCC,”
limited to the English written literature but with no restriction of
time. Two authors (MB and RD) have examined the titles of 1328
papers retrieved.
Papers that did not include HCC series and/or case reports
have been excluded, while ambiguous titles have been primarily
included, leaving 240 articles. A search on abstracts or full text
had led to the exclusion of other not pertinent papers. For trials
performed by the same research institute at different times, the
most recent and complete one has been included, unless different
methods or endpoints or specific issues had been addressed. We
also excluded the papers whose full text or at least abstract were
not available. The references of important and pertinent papers
have been searched for other relevant articles. At last 30 clinical
trials have been retrieved fulfilling the requisite for analysis.
ANGIOGENESIS INHIBITOR DRUGS
In recent times, the exact identification of cellular signaling
pathways playing a key role in the angiogenesis of HCC
(Figure 1), has lead to the development of new molecules for
targeted therapies (Table 1), (D’Amico et al., 2015a).
Bevacizumab
The prototypical angiogenesis inhibitor, bevacizumab, an anti-
VEGF monoclonal antibody directed against VEGF, is the first
anti-angiogenesis agent to be approved as an antineoplastic drug.
By neutralizing this ligand, bevacizumab prevents stimulation
of VEGFR and reduces the angiogenesis. As described above,
Bevacizumab given positive results both as a mono agent
and in combination either with several antiblastics (Gemox,
Folfox etc) or erlotinib in many phase II trials in advanced
HCC patients. (Zhu, 2006; Thomas et al., 2009; Hsu et al.,
2010; Sun et al., 2011). It should be noted, however, that
bleeding is an uncommon but well-documented side effect of
bevacizumab (Boige et al., 2012). In patients with HCC, such
bleeding is particularly dangerous as they often have underlying
coagulopathy secondary to liver dysfunction. A potential niche
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for bevacizumab may be as an adjunct to the Transarterial
chemoembolization (TACE) procedure. In one clinical trial, this
combination has shown to produce an impressive survival benefit
without adding substantial toxicity (Buijs et al., 2013). A study of
bevacizumab combined with erlotinib has reported 9.0 and 15.6
months in PFS and OS respectively, resulting in, an important
improvement of 4 months PFS (Thomas et al., 2009). In addition,
current phase II trial, also combining sorafenib vs. bevacizumab
and erlotinib (NCT00881751) is ongoing.
Brivanib
Brivanib is a TKI, with high specificity for both VEGFR and
FGF receptor (FGFR) signaling pathways (Cai et al., 2008). It
has shown hopeful anti-tumor activity in five of six patients
resistant to sorafenib (Huynh et al., 2008; Park et al., 2011;
Finn et al., 2012). Furthermore, in phase II trials for advanced
HCC patients, Brivanib as first-line agent has not achieved the
premeditated primary endpoint showing a 6 months PFS rate but
established an OS of 10 months. Particularly, the 10 months OS
has been higher than the 6.5 months OS in the Asia sorafenib
trial (Park et al., 2011), but TTP resulting simlar (2.8 months).
On the other hand, the numerous randomized phase III brivanib
trials in HCC patients at risk (BRISK) performed to estimate the
role of brivanib have also been unsatisfactory. In addition, in
patients who progressed on/after or were intolerant to sorafenib
the brivanib-post sorafenib (BRISK-PS) trial (NCT00825955)
evaluating brivanib vs. placebo, had not achieved the primary
endpoint of statistically improving OS (9.4 vs. 8.2 months, P =
0.3307) (Llovet et al., 2013). The BRISK-FL trial (NCT00858871)
has compared the safety and efficacy of brivanib and sorafenib in
patients with advanced/metastatic HCCwho were naïve for other
therapy. This investigation study has been also unsatisfactory but
has showed non-inferiority for brivanib vs. sorafenib. In fact,
in this study the primary endpoint in improving OS has failed
(9.5 months brivanib vs. 9.9 months sorafenib), and secondary
endpoints were alike in both study arms (Johnson et al., 2013).
Cabozantinib
The cabozantinib s-malate (salt form), is a small molecule
receptor TKI, bioavailable orally. This TKI drug binds to several
TK receptors, which are often over expressed in a lot of cancer cell
types, including hepatocyte growth factor receptor (MET), RET
(rearranged during transfection), and simultaneously inhibits
angiogenic factor receptor as VEGFR-1, VEGFR-2, and VEGFR-
3. In addition an inhibition ofmast/stem cell growth factor (KIT),
FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase,
endothelial), tropomyosin-related kinase B (TRKB), and AXL
lead to tumor regression (Roy et al., 2015).
Antitumor effects of cabozantinib, a dual inhibitor of MET
and VEGFR2, have been examined in cultured HCC cells
as well as in vivo models. In the study of Xiang et al.
(2014) phosphorylated MET (p-MET) has been measured in
29 resected HCC specimens, and have been correlated with
response to sorafenib as post-surgery adjuvant therapy. The
results have shown that high level of p-MET in resected
HCC specimens have been associated with resistance to
adjuvant sorafenib therapy. Cabozantinib has inhibited tumor
growth in p-MET-positive and p-MET-negative HCC by
decreasing angiogenesis, inhibiting proliferation, and promoting
apoptosis. Notably, in the experimental metastatic mouse model,
cabozantinib has reduced the number of metastasis in the lung
and liver. They have concluded that patients with HCC carrying
high level of p-MET are unresponsive to adjuvant treatment
with sorafenib. The double blockade of VEGFR2 and MET by
cabozantinib has significant antitumor activities in HCC, and
the activation of MET in HCC may be a promising efficacy-
predicting biomarker (Johnson et al., 2013).
Cediranib
Cediranib (AZD2171) is an additional multitargeted inhibitor
of VEGFR, PDGFRβ, FLT3 and c-KIT. In advanced HCC a
phase II clinical trial, recorded a 5.8 months OS and 2.8 months
TTP, and authors observed high occurrence of adverse events
concluding that Cediranib was not successful at schedule and
dosage of 45 mg/day (Alberts et al., 2012). A consequent phase II
study with cediranib at a reduced dose (30mg/day) demonstrated
inefficient antineoplastic effectiveness in advanced HCC with a
different acceptability profile. Results of the 5.3 months PFS and
11.7 months OS in this set were compared positively to data
reported with 45 mg/day dosing of cediranib in advanced HCC
(2.8 months TTP and 5.8 months OS). Prolongation of cure at a
dose of 30 mg/day and patient set bias might have contributed to
dissimilar outcome (Zhu et al., 2013a).
Everolimus
Everolimus, a rapamycin analog, inhibits themTOR pathway that
is a key regulator of growth, angiogenesis and tumor cell survival.
Since it is involved in hepatocarcinogenesis, m-TOR inhibition
with everolimus has been investigated in a randomized, placebo-
controlled Phase III trial (EVOLVE) in patients with Barcelona
clinic liver cancer B/C HCC after failure of sorafenib treatment
(Zhu et al., 2014b). Patients have been randomly assigned (2:1)
to treatment with everolimus (n = 362, 7.5mg QD) or placebo
(n = 184). The primary end point OS (7.6 vs. 7.3 months; HR
1.05, 95% CI 0.86–1.27; p = 0.675) as well as the TTP (3.0 vs. 2.6
months; HR 0.93, 95% CI 0.75–1.15) have been similar in both
arms. Thus, everolimus is considered to be inactive in patients
with HCC (Llovet, 2014).
Another study focused on the PI3K/Akt/mTOR signaling
cascade, as the activities of mTOR inhibitors and sorafenib, arise
at separate stages along two pathways, their combination could
be complementary and provide further successful suppression
of HCC. Although the combination of sorafenib and everolimus
have shown synergic inhibition of HCC. Further doubts relate to
the most effective means of administering the drug combination
and whether patients who have been unresponsive or intolerant
to sorafenib could subsequently benefit from an mTOR inhibitor
(Piguet et al., 2011).
Lenvatinib
Lenvatinib an oral multi-TKI of VEGFRs 1–3, FGFRs 1–
4, platelet-derived growth factor (PDGF) receptor alpha, and
KIT and RET and KIT proto-oncogenes (Schlumberger et al.,
2015). It was approved for radioiodine-refractory differentiated
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thyroid cancer, showing an impressive improvement in PFS
(Schlumberger et al., 2015). The hazard ratio (HR) for
progression or death was 0.21 with a 99% CI interval of 0.14
to 0.31 (p < 0.001) (Schlumberger et al., 2015). Additionally,
nearly 2/3 of the patients (64.8%) showed an objective response
(OR) to the lenvatinib treatment according to RECIST 1.1
criteria, including 4 complete responses. The most common
treatment-related adverse events were similar to other TKIs
(hypertension, diarrhea and fatigue). A total of 14% of the
patients were at need to stop treatment with lenvatinib due to
toxicity (Schlumberger et al., 2015). A further relevant safety
issue with should be kept under surveillance in other trials
investigating lenvatinib was the observation that 6 of 20 deaths
that occurred during the treatment period were considered to
be drug-related (Schlumberger et al., 2015). Currently, a Phase
III trial is investigating the safety and efficacy of lenvatinib vs.
sorafenib in the first-line setting (NCT01761266), for patients
with advanced HCC.
Linifanib
Linifanib (ABT-869), is a novel inhibitor of all VEGFR and
PDGFR tyrosine kinases (Albert et al., 2006). In an open
label, phase II trial, Linifanib as single agent demonstrated
significant clinical activity (OS 9.7 months and TTP 5.4 months)
in patients with advanced HCC (Toh et al., 2013). ABT-869
recorded a high acceptable safety profile in HCC patients.
Current randomized phase III trial is ongoing in 1035 patients
with advanced HCC who had no previous pharmacotherapy; it
evaluates the effectiveness of linifanib as first-line therapy vs.
sorafenib (NCT01009593). This trial has failed to account its
primary end point, showing a similar OS between linifanib and
sorafenib (9.1 months vs. 9.8 months respectively). TTP 5.4
months privileged linifanib vs. 4.0 months of sorafenib (Cainap
et al., 2015).
Nintedanib
Recently, an orally available TKI of VEGFR 1–3, PDGFR and
FGFR Nintedanib (BIBF 1120) has been developed. BIBF 1120
evidently inhibits tumor development and angiogenesis in an ex-
vivo model and exhibits moderately effects on HCC cell lines
(Hilberg et al., 2008; Kudo et al., 2011; Tai et al., 2014). In patients
with metastatic relapsed non-small cell lung cancer (NSCLC) and
poor prognosis, who had failed first-line chemotherapy, eligible
for phase II study (NCT00805194) shown remarkably benefit in
median PFS and OS, by nintedanib-based therapy (Tai et al.,
2014). A regimen for treatment of advanced ovarian cancer
combining nintedanib with carboplatin and paclitaxel is ongoing
(NCT01015118). Also in HCC patients, nintedanib is waiting to
being compared in terms of the efficacy/safety with sorafenib
(NCT01004003 and NCT00987935).
Ramucirumab
Ramucirumab is a monoclonal antibody wholly humanized,
designed to bind selectively to the extracellular domain VEGFR
2. This is a new therapeutic option as monotherapy or in
combination with paclitaxel that has shown to improve OS in
patients receiving second-line treatment for metastatic gastric
cancer (Fuchs et al., 2014; Wilke et al., 2014). In addition, a
phase II clinical trial in 42 patients with metastatic HCC has
demonstrated encouraging anticancer effect of ramucirumab,
showing 4 months median PFS and 12 months OS. The most
of patients evaluated in this trial had a well conserved liver
functions. An appealing result in this trial is the obtained
OS stratified by liver function difference. In fact the authors
reported a longer OS favoring ramucirumab in Child-Pugh B
group than Child-Pugh A group (18.0 months vs. 4.4 months).
Both groups are Barcelona clinic liver cancer-C (Zhu et al.,
2013b). The phase III REACH study, comparing ramucirumab
vs. placebo in patients with advanced HCC, after failure to
sorafenib, missed its primary end point. In fact the OS in
the intention-to-treat (ITT) patients (n = 565) has not been
significantly diverse between the ramucirumab and the placebo
group (HR 0.866, 95% confidence interval (CI) 0.717–1.046;
p = 0.1391; median OS 9.2 months for ramucirumab vs. 7.6
months for placebo). Nevertheless, ramucirumab has resulted in
a benefited PFS compared to placebo (HR 0.625, 95% CI 0.522–
0.750; p< 0.001; median PFS 2.8 months for ramucirumab vs. 2.1
months for placebo) in the ITT population, without any safety
concerns. However, in the subgroup of patients with baseline
α-fetoprotein (AFP) 400 ng/ml (n = 250) the OS has been
significantly longer for the patients treated with ramucirumab
(HR 0.67, 95% CI 0.51–0.90; p= 0.0059) with a median OS of 7.8
and 4.2 months for ramucirumab and placebo respectively (Zhu
et al., 2015). This data confirms that elevated value of AFP is a
poor prognostic factor. The reason why ramucirumab is more
efficacy in this setting is not clear, yet. Thus, ramucirumab will
be developed further in the similar population with elevated AFP
after sorafenib treatment progression or intolerance.
Refametinib
The MAPK/ERK kinases (MEK) 1 and 2 are downstream
components of the RAS signal transduction pathway, which
is constitutionally active in the case of a Ras mutation. Pre-
clinical studies indicate that activation of this pathway results in
increased tumor growth and apoptotic resistance (Roberts and
Der, 2007). Although mutations in the small GTPases of the Ras
family aremuch less frequent inHCC in comparison to colorectal
cancer (CRC) or pancreatic cancer, MEK inhibition seems to
be an effective approach in preclinical HCC models (Schmieder
et al., 2013). Refametinib (BAY 869766) is an allosteric inhibitor
ofMEK l/2 (Iverson et al., 2009). In a Phase II trial, 70 Asian HCC
patients have been treated with a combination of refametinib
and sorafenib (Lim et al., 2014). Four patients have shown an
objective response (OR). Duration of response in these four
patients has been 85, 128, 335, and 382 days, respectively. In
three of these patients responding to refametinib and sorafenib,
RAS mutations have been identified in plasma samples using
the BEAMing technology. BEAMing technology compromises
techniques such as PCR, hybridization and flow cytometry to
amplify circulating tumor-derived DNA, and has the capacity
to detect mutant DNA from or its fragments when present at
ratios>1:10000 (0.01%) (Lim et al., 2014). The observation that
patients with Ras mutations responded to the combination of
refametinib and sorafenib have led to the rationale to further
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explore refametinib in combination with sorafenib in patients
with HCC harboring a Ras mutation. Refametinib is currently
investigated in two Phase II trials either as monotherapy in
patients with advanced HCC who failed sorafenib treatment as
well as in combination with sorafenib in the first-line treatment
of advanced HCC (NCT01915589, NCT01915602).
Regorafenib
Regorafenib is an oral novel diphenylurea multikinase inhibitor
of VEGFR1–3, c-KIT, tyrosine kinase with immunoglobulin-like
and EGF-like domains-2, PDGFR-2, Fibroblast growth factor
receptor-1, RET, RAF-1, BRAF, and p38 MAP kinase (Strumberg
and Schultheis, 2012). Although it is structurally similar to
sorafenib, the addition of a fluorine atom in the central phenyl
ring might result in a higher efficacy. It has been approved
for the treatment of metastatic Colorectal cancer after failure
to oxaliplatin and irinorecan-based systemic chemotherapy
showing a significant improve of OS compared to placebo
arm (Strumberg and Schultheis, 2012). Moreover, it has also
been shown to be effective for the treatment of metastatic
gastrointestinal stroma tumors (GIST) after failure of imatinib
and sunitinib (Demetri et al., 2013). A multicenter, open label
phase II study in intermediate or advanced HCC patients who
failed to sorafenib has been reported showing a signal for activity
(Bruix et al., 2013). The side effect profile of regorafenib seems
acceptable and similar to sorafenib. Currently, a Phase III trial
(RESORCE) of regorafenib in patients who progressed under
sorafenib treatment is ongoing (NCT01774344).
Sorafenib
Sorafenib is an oral multi-kinase inhibitor that suppresses tumor
neo-angiogenesis and proliferation inhibiting the TK activities
of VEGFR 1–3 and of PDGFR-II. Moreover, it also inhibits
the serine-threonine kinase RAF-1 and B-Raf. The efficacy of
sorafenib has been demonstrated in two randomized controlled
trials. For convenience we report the data on SHARP trial,
where sorafenib has shown an improvement in OS (10.7 and.
7.9 months in the treatment and placebo arm respectively) and
good safety in patients with HCC, making sorafenib the standard
of care for the treatment of patients with advanced HCC (Llovet
et al., 2008). The high relapse rate of HCC after surgical resection
and/or local ablation has been the rational to start the STORM
trial, which tested adjuvant treatment with sorafenib vs. placebo
after R0 resection or complete ablation of HCC. Unfortunately,
sorafenib didn’t’ improve in PFS in this Phase III trial and at some
time has been associated with substantial side effects comparable
to adverse events reported in advancedHCC patients (Bruix et al.,
2014b). Therefore, adjuvant treatment with sorafenib should not
be suggested in patients with HCC after surgical resection and/or
local ablation.
Sorafenib Combined with Transarterial
Chemoembolization (TACE)
Even though initial responses to sorafenib, the situation of
advanced HCC treatment is still low and the majority of HCC
patients account loss of efficacy, with poor prognosis and less
than 1 year of survival (Berretta et al., 2015b). Conventional
TACE (cTACE) is a treatment able to improve (Lo et al., 2002;
Llovet et al., 2003) survival, with rates of 75%, 47% and 26%
at 1, 2 and 3 years respectively (Lo et al., 2002). Drug eluting
bead (DEB)-TACE is an evolution of cTACE in drug delivery to
raise loco-regional drug concentration (Hong et al., 2006; Varela
et al., 2007). It appears to notably go beyond the antiblastic
efficacy of TACE, with higher response rates ranging from 70
to 80%, while attenuation the adverse events (Reyes et al.,
2009; Lammer et al., 2010). A high prevalence of relapse is a
restriction of TACE, likely due to the up regulation of VEGF
and PDGFR, which sequentially increases tumor angiogenesis;
therefore, the combination of TACE with antiangiogenic drugs
has stranded out as an enhancement, aiming to decrease post-
TACE angiogenesis and the incidence of metastatic disease
and, as much as possible, improving loco-regional treatment
efficiency. A clinical trial with sorafenib joint with DEBTACE
(phase II study) in patients affected by advanced HCC has
shown a significant efficacy, 58% OR, about to 100% DCR,
and tumor size reduced by 4% (from 6.0 to 5.8 cm; P = 0.05)
after 1 combined therapy cycle (Pawlik et al., 2011). Quite a
few clinical trials have also demonstrated promising results for
combination targeted agents with TACE. One prospective non-
randomized controlled trial comparing the efficacy of sorafenib
in combination with TACE or TACE alone in unresectable or
advancedHCC revealed that the coactions of sorafenib prolonged
TTP (6.3 months vs. 4.3 months; P = 0.004) and the median
OS (7.5 months vs. 5.1 months; P = 0.009) (Bai et al., 2013).
Another retrospective multicenter study on 222 patients affected
by advanced HCC showed antitumor efficacy, with a 12 months
OS and 8.5 months TTP for the combination of sorafenib and
TACE. Promising, sorafenib in combination with TACE seems to
be a powerful treatment for patients affected by advanced HCC
(Zhao et al., 2013).
Sorafenib Combined with Antiblastic Chemotherapy
(AC) or Other Targeted Molecules
In several studies sorafenib decreased tumor size less clearly
when compared with placebo. However, AC shrinks the proper
dimensions of tumor, despite the lack of compelling proof in
benefiting survival for advanced HCC patients. Consequently,
several phase II/III clinical trials have been started worldwide to
evaluate sorafenib plus combination to sorafenib as monotherapy
(Sun et al., 2011). Sadly, the “sorafenib plus” combination
didn’t demonstrate advantage in clinical trials. The SEARCH
trial, sorafenib with erlotinib combination, a phase III study
(NCT00901901), showed no survival improve (OS 9.5 months
vs. 8.5 months, p = 0.204), according to the study reported at
the Congress in Vienna in 2012 by European Society for Medical
Oncology (ESMO).
Trebananib
Angiopoietins are vascular growth factors, binding to the Tie-2
receptor. Angiopoietin-1 mediates vessel maturation, adhesion,
migration and survival, whereas angiopoietin-2 promotes cell
death and disrupts vascularization. Trebananib (AMG386) is
an antiangiogenic compound that sequesters both angiopoietin-
1 and -2, thus preventing their interaction with the Tie-2
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receptor. To investigate the safety and efficacy of trebananib
plus sorafenib 60 patients affected by advanced HCC were
treated in a two-cohort, uncontrolled Phase II trial (cohort
1: Trebananib IV at 10mg/kg weekly; cohort 2: Trebananib
IV at 15mg/kg weekly) (Abou-Alfa et al., 2014). The primary
end point was PFS at 4 months. Although, trebananib at both
dose levels plus sorafenib was well tolerated, the study did
not show an improvement in PFS at 4 months compared
to a historical control. However, the median OS in the
10mg/kg cohort was 17 months, and the PFS was 9 months.
Currently, no further trial of trebananib in HCC is planned,
since the ovarian Phase III trial (TRINOVA-1) did not show
an improvement in OS (secondary end point) (Monk et al.,
2014).
Vatalanib
Vatalanib (PTK787), is a TKI that binds VEGFR by blocking
ATP-binding sites; it also inhibits both FLT-1 and Flk-1/KDR and
other class III TKr, such as PDGFR-II, FLT-4, c-kit, and c-fms
(Wood et al., 2000). A phase I/II research of vatalanib combined
with intravenous doxorubicin in advanced HCC was conducted,
reporting a 5.4 months PFS and 7.3 months OS. This was the
earliest trial combining TKI and doxorubicin that established
strong efficacy in advanced HCC patients and provided the
root for planning future trials combining anti-angiogenic agents
and AC to improve vatalanib effectiveness (Yau et al., 2010). A
preclinical study reported that the synergic activity of Vatalinib
and interferon/Fluorouracil allowing noticeably monitoring of
tumor development both in cell lines and a xenograft HCCmodel
(Murakami et al., 2011).
CONCLUSION
The angiogenesis is a dynamic essential process playing a
critical role in tumor growth and metastatic diffusion. The
development of new prognostic factors, tumor markers, imaging
techniques, and therapeutic modalities is the consequence of the
understanding the basic principles of the biology of angiogenesis.
Prognostic angiogenesis biomarker (i.e., VEGF level) plays a key
role in the circumstance of several cancer diseases.
Blocking angiogenesis represents an effective approach to
HCC. Current clinical and preclinical trials propose the benefit of
an arrangement of anti-angiogenic drugs with AC, radiotherapy
or other targeted drugs in several malignancies. Nevertheless, in
order to choose the optimal and most effective combination of
drugs (AC and anti-angiogenic), it is indispensable to knowledge
the mechanisms by which anti-angiogenesis effects could be
obtained. Validated molecular biomarkers, tissue histotype,
imaging and genetic could be integrated routinely into preclinical
and clinical trials, in order to choose the best possible scheduling
of these drugs, especially in the so called “frail patients” (Berretta
et al., 2011; Nunnari et al., 2012).
Unfortunately insufficient data are reported, also in clinical
trials, in so called “disadvantages” patients (HIV positive and
elderly) who represent a growing setting in the HCC “scenario”
(Nunnari et al., 2012; Di Benedetto et al., 2013a; Berretta et al.,
2015a).
We know that also in these patients the standard approach
used in the general population is safe and efficacy (Di Benedetto
et al., 2008, 2011, 2012, 2013b; Ursino et al., 2012; D’Amico et al.,
2015a,b; Berretta et al., 2015c).
Finally, we think that the recent progresses in genetics have
provided good opportunities to identify prognostic factors and
predictive markers of efficacy of antiangiogenic treatments.
Moreover, genetic markers could be a tool to identify responsive
patients to targeted therapies, and exclude patients at high risk to
develop severe adverse events. (De Monaco et al., 2014).
In the future, we believe that the right features of these
challenges are based on a multidisciplinary treatment approach,
in order to rationalize the costs of these treatments due to
aimed-interventions (Berretta et al., 2014).
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